Best of luck getting any company to provide exact information on what its costs and markup are for a particular product.
As regards vaccines supposedly being a big profit center for drug companies as antivaxers would have you believe, the reality is that vaccine revenue is a small part of the overall drug company bottom line, and few companies these days make vaccines - the number of firms producing them has declined from 26 in 1967 to only 5 as of 2004 (this contributes to periodic vaccine shortages - when production problems occur, there may not be sufficient capacity elsewhere to meet the demand, as was the case a few years ago when influenza vaccine shortages developed due to problems in an overseas plant).
Reasons for companies getting out of the vaccine business include the limited market for vaccines compared to drugs that are taken for many years, competition for resources used in drug development, industry mergers, a great reduction in the private vaccine market (government is by far the biggest purchaser of vaccines, and federal price caps limit payments; insurance company reimbursements to physicians for buying vaccines are only slightly above costs), and the higher development and production costs for vaccines as opposed to drugs (vaccines are held to a higher standard):
“…the current culture does not allow for any serious side effects from a vaccine. As a consequence, pharmaceutical companies are now asked to disprove even very rare adverse effects prior to licensure. Two companies, Merck and GlaxoSmithKline, are now testing rotavirus vaccines in pre-licensure trials that include more than 140,000 children. The cost of these two large trials is about $400 million. The added financial burden of now disproving rare adverse events before licensure is another disincentive to making vaccines.”
And finally of course there are product liability issues (fear of lawsuits, higher liability insurance costs). Vaccine makers began leaving the market after the mid-70s, when a British researcher published an ultimately disproved claim that the pertussis vaccine caused brain injury and other serious problems (hmm, does this sound familiar, Wakefield fans?). Even with the federal government stepping in to compensate people for findings of injury via a “vaccine court”, liability issues remain.
*"Unfortunately, three important weaknesses in the NVICP (vaccine injury compensation program) discourage vaccine makers. First, if dissatisfied with the outcome, people can always opt out of the NVICP and take their case to a jury. Parents claiming that their children were harmed by thimerosal (an ethylmercury-containing preservative in some vaccines) have sued vaccine makers; about 300 separate lawsuits are now pending in U.S. courts. Although four large epidemiologic studies found that children receiving thimerosal-containing vaccines were not at increased risk for the neurological problems claimed, plaintiffs’ lawyers are pressuring pharmaceutical companies for a large settlement.[22]
Second, the NVICP does not cover all vaccines, only those routinely recommended for all children…Third, the NVICP does not include the unborn child when the mother is immunized. For example, very young infants are occasionally infected by a bacterium called group B streptococcus (GBS). GBS infects the bloodstream, the brain, and the spinal cord. Every year, about 2,000 U.S. babies are infected with GBS and 100 die; more newborns die from GBS than any other infectious disease. Unfortunately, most vaccines in the United States and the world are not given until one or two months of age—too late to prevent GBS infections. Therefore, the most effective strategy to prevent GBS would be to immunize pregnant women. Researchers have already shown that a GBS vaccine given to pregnant women would work to protect newborns.[24] However, because of concerns about litigation following immunization of pregnant women, no pharmaceutical company is willing to make a GBS vaccine or any vaccine that would include maternal immunization."*
(the above quotes are from a Medscape article I can’t link to directly - try Googling “are fewer companies making vaccines now”).